Compounded preparations are dispensed only on a doctor’s prescription.
Short answer: A 2026 systematic review and meta-analysis reported that royal jelly supplementation improved postmenopausal symptoms compared with placebo, with moderate-quality evidence, across two studies of 312 participants (PMID 41401249). A 2019 placebo-controlled trial of 200 postmenopausal women found symptom scores fell over eight weeks, and its authors called for further research (PMID 31470366).
Why women ask about royal jelly
Royal jelly is a bee product, taken as a dietary supplement. Its use in menopause has been studied in a limited number of studies (PMID 41401249).
What the systematic review reports
The 2026 review in Menopause searched MEDLINE, LILACS, Embase and the Cochrane Library through May 2025, and included studies that evaluated postmenopausal symptoms, including genitourinary symptoms and quality-of-life measures. Of 281 records identified, six studies involving 471 postmenopausal women were included in the final analysis, published between 2011 and 2021 (PMID 41401249). For the pooled comparison of royal jelly with placebo, the authors report a standardised mean difference of 0.73 in postmenopausal symptoms, based on two studies and 312 participants, with moderate-quality evidence (PMID 41401249).
The authors conclude that “RJ supplementation may offer a promising nonhormone option for managing menopausal symptoms and supporting bone and genitourinary health, especially for women who cannot or prefer not to use hormone therapy” (PMID 41401249). The authors frame this as a possibility, and the pooled comparison rests on only two studies (PMID 41401249).
The single placebo-controlled trial
A double-blind randomised trial in Bandar Abbas, Iran, enrolled 200 postmenopausal women aged 45 to 60 years. Each participant received either 1,000 mg of royal jelly capsules or placebo daily for eight weeks (PMID 31470366). The menopausal score reduced significantly after eight weeks in the royal jelly group, and the reduction was not significant in the control group (PMID 31470366). The authors concluded that daily oral royal jelly was effective in alleviating menopausal symptoms, but added that further research is necessary to confirm the effects (PMID 31470366).
| Study | Design and population | Outcome as reported | PMID |
|---|---|---|---|
| Menopause, 2026 | Systematic review and meta-analysis; six studies, 471 women (two studies, 312 participants pooled) | Standardised mean difference 0.73 for postmenopausal symptoms versus placebo; moderate-quality evidence | 41401249 |
| Complementary Therapies in Clinical Practice, 2019 | Double-blind randomised placebo-controlled trial; 200 postmenopausal women aged 45 to 60 | Menopausal score reduced significantly in the royal jelly group, not significantly in controls | 31470366 |
What the evidence does not yet settle
The pooled estimate rests on two studies in the meta-analysis, and the trial that reports the clearest single-study result was carried out in Bandar Abbas, Iran (PMID 31470366). Neither source reports long-term safety beyond the trial period, and the abstracts do not give a validated dose for postmenopausal use outside the trial. Human evidence of benefit for royal jelly in menopausal symptoms rests on the limited number of studies (PMID 41401249; PMID 31470366) and is not established beyond them.
Breast cancer and hormonal effects
A 2024 literature review of the hormonal effects of royal jelly describes the data on cancer as controversial. Its abstract states that future clinical studies are essential to confirm the safe dose of royal jelly as an adjuvant therapy in breast cancer (PMID 38717683). Women with a history of hormone-sensitive breast cancer, or who are being monitored for it, should discuss royal jelly with their oncology or primary-care doctor before use.
Allergy and anaphylaxis
Royal jelly carries an allergy risk. A 2013 study of enzyme-treated royal jelly states that royal jelly is known to induce an anaphylactic response in some individuals, and its authors examined a protease-treated product for reduced allergenicity in people sensitive to royal jelly (PMID 23563566). The study’s own results concern the treated product in a small number of sensitised patients, so they cannot be read as a general statement about royal jelly. Anyone with a known bee-product allergy should not start royal jelly without medical advice.
Interactions and prescribed medicines
Women on hormone therapy, anticoagulants or other prescription medicines should tell their prescriber before starting any royal jelly product. The sources in this article do not establish an interaction profile, so the prescriber’s review is the safeguard.
Related Lynnity articles
Readers interested in hormone-based options for menopause can read the Lynnity guide to how BHRT helps with menopause-related bone loss, liver fat and lipid changes, and the Lynnity page on menopause treatment in Malaysia, which describes the clinical pathway.
How to get this prescribed
Lynnity prepares royal jelly from its own stock as a non-sterile compounded preparation, on a registered doctor’s prescription, for one named patient. Lynnity holds royal jelly in stock as a powder and as a liquid. According to the Lynnity formulary record, the permitted forms for royal jelly are capsule, liquid (liposomal solution), powder, cream, serum, gel and spray.
Ask your doctor to send the prescription to Lynnity. The strength, quantity and directions are the prescriber’s to specify. For questions about the process, use the Lynnity contact page, and the GCP laboratory page describes the non-sterile work.
Frequently asked questions
Does royal jelly help with menopausal symptoms?
A 2026 meta-analysis reports a benefit over placebo across two pooled studies with moderate-quality evidence, and a 2019 trial of 200 women found symptom scores fell over eight weeks (PMID 41401249; PMID 31470366). The 2019 trial’s authors add that further research is necessary, so the evidence is limited.
Is royal jelly safe for women with allergies?
A 2013 study states that royal jelly is known to induce an anaphylactic response in some individuals (PMID 23563566). Women with a bee-product allergy should seek medical advice before starting it.
Can royal jelly replace hormone therapy?
The 2026 review describes royal jelly as a possible nonhormone option for women who cannot or prefer not to use hormone therapy (PMID 41401249). It does not show equivalence to hormone therapy, so decisions about hormone therapy remain with the prescriber.
Who should ask a doctor before using royal jelly?
Women with a history of hormone-sensitive breast cancer, and women with a known bee-product allergy, should ask their doctor first. The 2024 review states that future clinical studies are essential to confirm a safe dose (PMID 38717683). A 2013 study reports that royal jelly is known to induce an anaphylactic response in some individuals (PMID 23563566).
Reviewer
Reviewed by Vitthia Rama Murti, RPh (RPh 15632).